BS_X59HSFGG
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 57.68725361366623
- age_years
- 13.926
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.634
- INTERFERON_GAMMA_RESPONSE+0.584
- MYC_TARGETS_V2+0.484
- CHOLESTEROL_HOMEOSTASIS+0.481
- ANDROGEN_RESPONSE+0.477
- ALLOGRAFT_REJECTION+0.476
- IL6_JAK_STAT3_SIGNALING+0.449
- UNFOLDED_PROTEIN_RESPONSE+0.448
- MTORC1_SIGNALING+0.443
- TNFA_SIGNALING_VIA_NFKB+0.435
Top 10 suppressed
- SPERMATOGENESIS-0.203
- WNT_BETA_CATENIN_SIGNALING-0.180
- PANCREAS_BETA_CELLS-0.177
- HEDGEHOG_SIGNALING-0.143
- KRAS_SIGNALING_DN-0.141
- HEME_METABOLISM-0.039
- APICAL_SURFACE-0.022
- UV_RESPONSE_DN-0.007
- BILE_ACID_METABOLISM+0.006
- APICAL_JUNCTION+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.921 |
| 2 | EC7327B2-6767-4005-9C51-005957C1F923 | — | — | 0.918 |
| 3 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.917 |
| 4 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.916 |
| 5 | SRR934921 | — | — | 0.916 |
| 6 | SRR8942975 | — | — | 0.916 |
| 7 | C3F0BD22-6891-44F0-B023-02FC6EDFA7EB | — | — | 0.915 |
| 8 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.911 |
| 9 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.909 |
| 10 | 5C40F9B6-4A54-4861-9DE5-8852BF4B13E7 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.634 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.584 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.484 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.481 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.477 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.476 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.449 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.448 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.443 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.435 | Inavolisib | — uncovered |
| COMPLEMENT | 0.425 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.425 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.367 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.355 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.353 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.289 | Inavolisib | — uncovered |
| COAGULATION | 0.286 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.279 | Inavolisib | — uncovered |